NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 356 filers reported holding NEKTAR THERAPEUTICS in Q1 2019. The put-call ratio across all filers is 1.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $38,280 | -68.0% | 54,460 | +3.0% | 0.00% | -100.0% |
Q4 2022 | $119,511 | -26.2% | 52,881 | +4.5% | 0.00% | -50.0% |
Q3 2022 | $162,000 | -14.7% | 50,620 | +1.2% | 0.00% | 0.0% |
Q2 2022 | $190,000 | -29.4% | 50,015 | +0.3% | 0.00% | 0.0% |
Q1 2022 | $269,000 | -59.7% | 49,889 | +0.8% | 0.00% | -60.0% |
Q4 2021 | $668,000 | -25.1% | 49,470 | -0.4% | 0.01% | -28.6% |
Q3 2021 | $892,000 | +6.6% | 49,660 | +1.8% | 0.01% | 0.0% |
Q2 2021 | $837,000 | -19.8% | 48,765 | -6.6% | 0.01% | -22.2% |
Q1 2021 | $1,044,000 | +18.4% | 52,223 | +0.7% | 0.01% | +12.5% |
Q4 2020 | $882,000 | -1.0% | 51,881 | -3.4% | 0.01% | -11.1% |
Q3 2020 | $891,000 | -3.2% | 53,706 | +35.3% | 0.01% | -30.8% |
Q2 2020 | $920,000 | +24.8% | 39,707 | -3.9% | 0.01% | 0.0% |
Q1 2020 | $737,000 | -65.8% | 41,300 | -58.6% | 0.01% | -50.0% |
Q4 2019 | $2,153,000 | +261.2% | 99,760 | +204.8% | 0.03% | +271.4% |
Q3 2019 | $596,000 | -49.5% | 32,728 | -1.3% | 0.01% | -50.0% |
Q2 2019 | $1,180,000 | -54.1% | 33,152 | -56.7% | 0.01% | -54.8% |
Q1 2019 | $2,572,000 | +2.6% | 76,557 | +0.4% | 0.03% | -3.1% |
Q4 2018 | $2,507,000 | -63.0% | 76,271 | -31.3% | 0.03% | -50.0% |
Q3 2018 | $6,769,000 | +51.0% | 111,036 | +20.9% | 0.06% | +42.2% |
Q2 2018 | $4,484,000 | +5.8% | 91,825 | +130.1% | 0.04% | +4.7% |
Q1 2018 | $4,240,000 | -73.2% | 39,900 | -84.9% | 0.04% | -72.1% |
Q4 2017 | $15,806,000 | +711.8% | 264,668 | +226.2% | 0.15% | +569.6% |
Q3 2017 | $1,947,000 | +23.1% | 81,145 | +0.2% | 0.02% | +4.5% |
Q2 2017 | $1,582,000 | -15.9% | 80,945 | +1.0% | 0.02% | -15.4% |
Q1 2017 | $1,881,000 | +94.9% | 80,145 | +1.9% | 0.03% | +85.7% |
Q4 2016 | $965,000 | -20.6% | 78,645 | +11.2% | 0.01% | -22.2% |
Q3 2016 | $1,215,000 | +20.7% | 70,745 | 0.0% | 0.02% | +28.6% |
Q2 2016 | $1,007,000 | +5.1% | 70,745 | +1.6% | 0.01% | +16.7% |
Q1 2016 | $958,000 | -14.5% | 69,645 | +4.8% | 0.01% | -20.0% |
Q4 2015 | $1,120,000 | +60.9% | 66,445 | +4.6% | 0.02% | +50.0% |
Q3 2015 | $696,000 | – | 63,545 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HARVEY CAPITAL MANAGEMENT INC | 598,400 | $10,083,000 | 3.98% |
Opus Point Partners Management, LLC | 348,583 | $5,874,000 | 3.88% |
Camber Capital Management LP | 3,500,000 | $58,975,000 | 3.81% |
1492 Capital Management LLC | 180,601 | $3,043,000 | 2.21% |
Virtus ETF Advisers LLC | 38,260 | $645,000 | 1.77% |
Cormorant Asset Management, LP | 765,156 | $12,893,000 | 1.54% |
Rhenman & Partners Asset Management AB | 581,000 | $9,790,000 | 1.48% |
Granahan Investment Management | 2,082,155 | $35,084,000 | 1.21% |
BRIDGER MANAGEMENT, LLC | 1,563,862 | $26,351,000 | 0.87% |
RICE HALL JAMES & ASSOCIATES, LLC | 899,531 | $15,157,000 | 0.87% |